From: Systematic review of pharmacological treatments in fragile X syndrome
 | Folic acid (FA) |  |  |
---|---|---|---|
Reference | Participants and Follow-Up Period | Methods | Interventions |
Brown 1984 [21] | N = 2 brothers, 10.5 and 18.8 years. Setting: in-patients. FUP: 16 days | R, CO, DB. AASG: no; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 1,6 mg/kg intravenous vs Placebo |
Brown 1986 [22] | N = 5 males, 8 to 26 years. 3 autism FUP: 9 months | R, CO, DB. AASG: unclear; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 250 mg/day vs Placebo |
Carpenter 1983 [23] | N = 4 males, 2 to 10 years. IQs: 45 to 50. 2 autistic behaviour. FUP: 6 months | NR, CO, DB. AASG: no; AAC: unclear; AB: unclear; IDAA: unclear; FSR: unclear. | FA 10 mg/day vs Placebo |
Fisch 1988 [24] | N = 6 males, 3.5 to 15 years. 3 autistic, 3 mental retardation only (borderline to severe). FUP: 12 months | R, CO, DB, SA. AASG: unclear; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 10 mg/day vs Placebo |
Froster-Iskenius 1986 [29] | N = 10 males, 15 to 54 years. IQ: 21 to 60. FUP: 4 months | R, P, DB. AASG: unclear; AAC: unclear; AB: no; IDAA: yes; FSR: yes. | FA 10 mg/day vs 0.0015 mg of folic acid/day, 2 months and 2 months with folic acid, 10 mg/day |
Gillberg 1986 [30] | N = 4 males, 6 to 14 years. IQ: 39 to 64. All autism, 3 epilepsy. FUP: 9 months | NR, CO, DB, SA. AASG: no; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 5 mg/day vs Placebo |
Hagerman 1986 [25] | N = 25 males, 1 to 31 years. IQ: 39 to 82. Many of the younger ones in special education program with language and occupational therapy. Many adults use phenothiazines. FUP: 12 months | R, CO, DB, SA. AASG: yes; AAC: unclear; AB: yes; IDAA: yes; FSR: yes. | FA 10 mg/day vs Placebo |
Madison 1986 [26] | N = 3 males, 3, 8 and 12 years old. Moderate mental retardation. FUP: 11 weeks | NR, DB. AASG: no; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | No drug-no placebo (20 days). Placebo (13-45 days). Folic acid 10 mg/day (10-43 days) |
Rosenblatt 1985 [28] | N = 2 monozygous male twins, 14 years old, mentally retarded. FU: 12 months | NR, CO. AASG: no; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 5 mg/day vs Placebo |
Strom 1992 [27] | N = 21 males, 2-22 years, mean 8.3 years. FUP: 24 weeks | R, CO, DB, SA. AASG: unclear; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 15 mg/day vs Placebo |
 | Ampakine compound CX516 |  |  |
Berry-Kravis 2006 [14] | N = 49. 11 female, 18-49 years. IQ: 36 to75, mean 43; 12 ≥50. Autism 21, spectrum: 4. 27 on psychoactive medication. FUP: 4 weeks | Phase II, R, P, DB, SA. AASG: yes; AAC: yes; AB: yes; IDAA: yes; FSR: yes. | Ampakine compound CX516 600-900 mg/day vs Placebo |
 | Dextroamphetamine Methylphenidate |  |  |
Hagerman 1988 [5] | N = 15, 2 female. 3.8-11.8 years. IQ: 29 to 77 (3 IQ >70). All attentional problems. 40% on stimulants. FUP: 3 weeks | R, CO, DB, SA. AASG: unclear; AAC: unclear; AB: yes; IDAA: yes; FSR: yes. | Dextroamphetamine 2 mg/kg/day vs Methylphenidate 0.6 mg/kg/day vs Placebo |
 | L-Acetylcarnitine |  |  |
Torrioli 1999 [32] | N = 20 males, 6-13 years. IQ:30 to 69 Hyperactive behaviour. FUP: 12 months | R, P, DB, SA. AASG: unclear; AAC: unclear; AB: unclear; IDAA: unclear; FSR: yes. | L-Acetylcarnitine 100 mg/kg/day vs Placebo |
Torrioli 2008 [13] | N = 63 males, 6-13 years, all with Attention Deficit Hyperactivity Disorder. All extra care and stimulation at school and home, and visits by neuropsychiatrists. FUP: 12 months | Phase II, R, P, DB, SA. AASG: unclear; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | L-Acetylcarnitine 20-50 mg/kg/day vs Placebo |